Last reviewed · How we verify
T-DM1 and Pertuzumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
T-DM1 and Pertuzumab (T-DM1 and Pertuzumab) — QuantumLeap Healthcare Collaborative.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| T-DM1 and Pertuzumab TARGET | T-DM1 and Pertuzumab | QuantumLeap Healthcare Collaborative | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- T-DM1 and Pertuzumab CI watch — RSS
- T-DM1 and Pertuzumab CI watch — Atom
- T-DM1 and Pertuzumab CI watch — JSON
- T-DM1 and Pertuzumab alone — RSS
Cite this brief
Drug Landscape (2026). T-DM1 and Pertuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/t-dm1-and-pertuzumab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab